The rising prevalence of diabetes among active populations across the world is becoming a major public health concern, especially in low and middle-income countries having a heavy dependence on starch-based diets. These countries usually face a problem of limited access to pharmaceutical products which tend to be relatively expensive. Thus, a diet-based approach can be a more plausible option for the management of type II diabetes. Recent clinical studies, mainly involving animal trials suggest that continuous intake of germinated brown rice (GBR) products can provide a cheaper approach in the management of several chronic diseases, including Diabetes Mellitus. To validate these claims in relation to type II diabetes care a pilot clinical trial involving twenty (20) diabetes patients (subjects) was conducted in the Bo Government Hospital, Sierra Leone. A double-blind parallel arm clinical trial involving two groups of type II diabetic subjects put on a continuous diet of normal parboiled brown rice (PBR) and parboiled germinated brown rice (PGBR) was conducted over a period of 4 months. Three sets of data were collected to compare the effects of PGBR and PBR diets on the blood glucose levels, blood pressure, body mass index (BMI) and general well-being of participating subjects. The acceptability of rice treatments was also determined through continuous subjective evaluations conducted over the course of the trial. The results show positive effects from both treatments in relation to all indicators considered. However, PGBR appeared to have a greater effect than PBR in terms of the depression of blood glucose (27.8 and 5.7) systolic (12.7 and 2.9) and diastolic blood pressure (13.6 and 3.6), BMI (4.69 and -1.21), and general wellbeing of the subjects respectively. The study further suggests that the acceptability of both products (PGBR and PBR) was similar and very high (≥ 97.4% for both treatments). While the results obtained in this study corroborate the growing evidence supporting the use of germinated rice products as alternatives to diabetes management and care.